By Melane Sampson
Closely held Cell Technologies is advancing regenerative medicine through proprietary autologous and allogeneic stem cell platforms designed to treat the pain and inflammation associated with osteoarthritis (OA) and degenerative disc disease (DDD)—two large, underserved markets with significant clinical and economic burden.
“In the U.S. alone more than 14 million individuals suffer from knee OA. There is a significant addressable market with clear unmet need—representing a more than $15 billion opportunity,” Riam Shammaa, MD, CCFP(SEM), founder, president, and director of Cell Technologies, says in an interview with BioTuesdays.
OA is the most common degenerative joint disease, and the most common form of arthritis, affecting millions worldwide as a leading cause of disability in older adults. It occurs when cartilage cushioning the joint breaks down over time, often leading to pain, stiffness, and reduced mobility in the knees, hips, and hands.
DDD is a condition where the discs of the spine break down, causing pain and other problems in the spine. This condition commonly affects the cervical (neck) and lumbar (low back) regions of the spine because these regions move quite a bit, resulting in greater wear.
Dr. Shammaa explains that OA and DDD often lead to long-term disability, reduced quality of life, and escalating health care costs. Current treatment options—ranging from anti-inflammatory medications and injections to joint replacement surgery—offer limited durability or come with substantial costs and recovery times.
He adds that Cell Technologies is positioning its regenerative therapies within the treatment gap between conservative care and surgery, with the goal of restoring function while reducing inflammation and delaying or preventing invasive procedures.
The company’s dual platform strategy targets immediate and long-term opportunity. Its technology is built on two complementary approaches: autologous therapy—using a patient’s own cells, and allogeneic therapy—using cells derived from healthy donors.
Cell Technologies’ lead autologous product, Chondrostem (CLL-001), utilizes bone marrow-derived stem cells that are processed and delivered at the point of care. Dr. Shammaa explains that the therapy is designed to maintain high cell viability by avoiding freezing and thawing, a process that can compromise cell function.
“Our autologous platform delivers fresh, viable stem cells directly to the patient in a single office procedure administered in roughly 30 minutes,” he says. “We believe this approach enhances cell functionality and therapeutic impact.”
Meanwhile, the company’s allogeneic platform is engineered for scalability and broader commercial application. Using donor-derived cells cultured under hypoxic conditions—meaning the cells are created in a low-oxygen environment of approximately 5% atmospheric oxygen—the therapy aims to deliver high cell counts with consistent quality while maintaining ease of administration.
“We see allogeneic therapy as the future of regenerative medicine due to its scalability and cost efficiency,” Dr. Shammaa says. “It has the potential to function much like other widely adopted biologics.”
Both platforms are designed to generate approximately 100 million viable cells per dose—significantly higher than many competing approaches—and are supported by the company’s proprietary patented technologies.
Cell Technologies is preparing to initiate a Phase 3 clinical trial in the fourth quarter of 2026, following encouraging results from prior studies.
According to Dr. Shammaa, Phase 2 data demonstrated that approximately 60% experienced significant and sustained pain reduction compared to control groups, along with 90% improvement in function and quality of life.
“We observed sustained pain relief out to 12 months and beyond, along with a 90% functional increase. This is highly meaningful for patients,” Dr. Shammaa notes.
He adds that the planned Phase 3 trial will include patients across the spectrum of disease severity, including mild-to-severe OA, and will incorporate a crossover design, allowing patients in the control arm to receive treatment after an initial evaluation period.
The company is pursuing regulatory pathways in the U.S. and Canada and is targeting potential accelerated approval strategies where applicable.
Dr. Shammaa points out that the regenerative medicine market is projected to reach approximately $150 billion by 2028, growing at a compound annual rate exceeding 20%. Within this broader landscape, OA represents a particularly attractive segment due to its high prevalence and limited treatment innovation.
He says that patients with OA often face a long and costly treatment journey. Conservative therapies such as NSAIDs, corticosteroid injections, and platelet-rich plasma typically provide only short-term relief, while joint replacement surgery can cost more than $45,000 and involve lengthy recovery periods.
Cell Technologies aims to offer a cost-effective alternative, with treatment costs estimated at approximately $7,000 per dose.
“We are targeting the space between failed conservative treatments and surgery,” Dr. Shammaa contends. “Our goal is to delay or prevent joint replacement while improving patient outcomes.”
In addition to clinical benefits, Dr. Shammaa highlights the broader economic impact of OA, noting that a significant proportion of patients who transition to disability do not return to work within six months.
Commenting on the competitive landscape and industry momentum, Dr. Shammaa emphasizes that interest in regenerative medicine has accelerated following recent regulatory milestones, including the January 2025 FDA approval of Mesoblast’s (NASDAQ: MESO) Ryoncil for graft-versus-host disease.
“Many in the industry view the Mesoblast approval as a validation of cell-based therapies and a potential catalyst for increased investment and development activity,” he says.
Within the OA space, Dr. Shammaa believes Cell Technologies is well positioned due to its clinical-stage progress, high cell-dose approach, and focus on maintaining cell viability through fresh, non-frozen delivery.
“There is relatively limited competition at our stage in OA,” he contends. “We believe our approach offers meaningful differentiation in both efficacy and delivery.”
Cell Technologies is pursuing a capital-efficient business model centered on strategic licensing partnerships, and driving multiple assets to the market through its proprietary platforms.
“We are focused on minimizing infrastructure requirements while maximizing reach through partnerships,” Dr. Shammaa says.
The company is also engaged in discussions with pharmaceutical partners for its allogeneic platform, which may offer broader global scalability.
To support its next phase of growth, Cell Technologies is currently raising $25 million in a Series A financing to fund its Phase 3 trial and advance toward a potential public listing.
The company’s intellectual property portfolio includes six patents extending through 2039, covering its core technologies.
Dr. Shammaa’s extensive experience in cell therapy and biologics, along with his involvement in numerous early innovations in regenerative medicine, is complemented by a broader leadership team of industry executives with proven experience in building and scaling biotechnology companies.
“Our management team has deep experience in medical innovation with successes running publicly held companies and driving assets to market—they’ve done it all before,” Dr. Shammaa says.
He underscores that with a leadership team experienced in late-stage development, Phase 3 readiness, a differentiated dual-platform strategy, and a large addressable market, Cell Technologies is emerging as a credible contender in the regenerative medicine space.
Beyond OA and DDD, the company is exploring applications for its platform, including wound healing and cardiac conditions.
Dr. Shammaa indicates that as the regenerative medicine field continues to evolve, Cell Technologies aims to capitalize on growing clinical validation, increasing investor interest, and a clear need for more effective, less invasive treatment options.
“Our focus now is on executing our Phase 3 program and continuing to expand our pipeline,” he concludes. “We believe our technology has the potential to address multiple high-impact indications.”
A Patient’s Story: A Life Restored
Before ChondroStem™
After ChondroStem™
• • • • •
To connect with Cell Technologies or any other companies featured on BioTuesdays, send us an email at editor@biotuesdays.com.
